Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients

European Journal of Human Genetics

Volumn 21, Issue 12, 2013, Pages 1383-1388

  Corso, Giovanni ^a   Pascale, Valeria ^a   Flauti, Giuseppe ^a   Ferrara, Francesco ^a   Marrelli, Daniele ^a   Roviello, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

colorectal cancer; microsatellite instability; oncogenic mutation

Indexed keywords

MOLECULAR MARKER;

ANATOMY; ARTICLE; BRAF GENE; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; COLON CARCINOMA; COLORECTAL CANCER; EGFR GENE; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE; ONCOGENE K RAS; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MUTATION; ONCOGENES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887618965     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.66     Document Type: Article

References (43)

1. Imajo M, Tsuchiya Y, Nishida E: Regulatory mechanisms and functions of MAP kinase signaling pathways. IUBMB Life 2006; 58: 312-317.
2. Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem1990; 265: 7709-7712.
3. Quian XL, Decker SJ, Greene MI: p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc Natl Acad Sci USA 1992; 89: 1330-1334.
4. Lynch TJ: The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. Clin Adv Hematol Oncol 2004; 2: 786-787.
5. Artale S, Sartore-Bianchi A, Veronese SM et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219.
6. Allegra CJ, Jessup JM, Somerfield MR et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
7. Velho S, Oliveira C, Seruca R: KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol 2009; 27: 158-159.
8. Yen LC, Uen YH, Wu DC et al: Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251: 254-260.
9. Metzger B, Chambeau L, Begon DY et al: The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet 2011; 12: 144.
10. Nagahara H, Mimori K, Ohta M et al: Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005; 11: 1368-1371.
11. Yuan Z, Shin J, Wilson A et al: An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res 2009; 69: 7811-7818.
12. Deqin M, Chen Z, Nero C et al: Somatic deletions of the polyA tract in the 30 untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med 2012; 136: 510-516.
13. Velho S, Corso G, Oliveíra C, Seruca R: KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. Adv Cancer Res 2010; 109: 123-143.
14. Miyaki M, Iijima T, Yamaguchi T et al: Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 2007; 121: 1627-1630.
15. Gulhati P, Zaytseva YY, Valentino JD et al: Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis 2012; 33: 1782-1790.
16. Corso G, Velho S, Paredes J et al: Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011; 47: 443-451.
17. Corso G, Pedrazzani C, Marrelli D, Pascale V, Pinto E, Roviello F: Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch Surg 2009; 144: 722-727.
18. Phipps AI, Scoggins J, Rossing MA, Li CI, Newcomb PA: Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007. Am J Public Health 2012; 102: 1791-1797.
19. Kalady MF, Dejulius KL, Sanchez JA et al: BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012; 55: 128-133.
20. Wong R: Proximal tumors are associated with greater mortality in colon cancer. J Gen Intern Med 2010; 25: 1157-1163.
21. Li FY, Lai MD: Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 2009; 10: 219-229.
22. Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R: Study Group 'Colon/Rectum Carcinoma (Primary Tumor)': Colon carcinoma- classification into right and left sided cancer or according to colonic subsite?-Analysis of 29,568 patients. Eur J Surg Oncol 2011; 37: 134-139.
23. Oliveira C, Westra JL, Arango D et al: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-2311.
24. Sylvester BE, Huo D, Khramtsov A et al: Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 2012; 18: 350-359.
25. Roth AD, Tejpar S, Delorenzi M et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
26. Webster J, Kauffman TL, Spencer Feigelson H et al: KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev 2012; 22: 91-101.
27. Cai G, Xu Y, Lu H et al: Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int J Colorectal Dis 2008; 23: 365-373.
28. Gryfe R, Kim H, Hsieh ET et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
29. Malesci A, Laghi L, Bianchi P et al: Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13: 3831-3839.
30. Clark AJ, Barnetson R, Farrington SM, Dunlop MG: Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer 2004; 3: 85-91.
31. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003; 106: 66-73.
32. Carethers JM, Chauhan DP, Fink D et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-131.
33. Carethers JM, Smith EJ, Behling CA et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
34. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Morere JF: Microsatellite instability: a predictive marker in metastatic colorectal cancer? Target Oncol 2009; 4: 57-62.
35. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-1896.
36. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF: Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer? A systematic review and meta-analysis. Anticancer Res 2009; 29: 1615-1620.
37. Ribic CM, Sargent DJ, Moore MJ et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
38. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-373.
39. Oliveira C, Pinto M, Duval A et al: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003; 22: 9192-9196.
40. Campbell IG, Choong D, Chenevix-Trench G: Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer: No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. Breast Cancer Res 2004; 6: R366-R371.
41. Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224.
42. Velho S, Oliveira C, Ferreira A et al: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-1654.
43. Liao X, Morikawa T, Lochhead P et al: Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-2268.